Rohan R Katipally
Overview
Explore the profile of Rohan R Katipally including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arshad M, Lynch C, Katipally R, Pitroda S, Weichselbaum R
Oncotarget
. 2025 Mar;
16:163-166.
PMID: 40079896
No abstract available.
2.
Lynch C, Korpics M, Katipally R, Bestvina C, Pitroda S, Patel J, et al.
Eur J Cancer
. 2024 Aug;
209:114264.
PMID: 39106643
Background: Stereotactic body radiotherapy (SBRT) is safe and effective for treatment of extracranial metastatic disease, but its safety when combined with immune checkpoint inhibitors (ICI) has not yet been comprehensively...
3.
Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer
Rajeev-Kumar G, Katipally R, Li S, Shogan B, Olortegui K, Chin J, et al.
Cancer J
. 2024 Jul;
30(4):256-263.
PMID: 39042777
Locally advanced rectal cancer has historically been treated with multimodal therapy consisting of radiation therapy, chemotherapy, and total mesorectal excision. However, recent prospective trials and registry studies have demonstrated similar...
4.
Lynch C, Arshad M, Katipally R, Pitroda S, Weichselbaum R
J Clin Oncol
. 2024 Jul;
42(29):3387-3391.
PMID: 39038267
Sharing the burden of low-volume metastatic cancer between ICB and local treatments.
5.
Gutman M, Serra L, Koshy M, Katipally R
Semin Intervent Radiol
. 2024 Mar;
41(1):1-10.
PMID: 38495259
This review summarizes the clinical evidence supporting the utilization of stereotactic body radiotherapy (SBRT) for liver tumors, including hepatocellular carcinoma, liver metastases, and cholangiocarcinoma. Emerging prospective evidence has demonstrated the...
6.
Lynch C, Korpics M, Katipally R, Wu T, Bestvina C, Pitroda S, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jan;
118(5):1519-1530.
PMID: 38199382
Purpose: Stereotactic body radiation therapy (SBRT) safely and effectively controls liver metastases (LMs), but its safety and efficacy when combined with immune checkpoint inhibitors (ICIs) are not well characterized. This...
7.
8.
Wang L, Katipally R, Liang H, Yang K, Pitroda S, He C, et al.
Med
. 2023 Dec;
4(12):863-874.
PMID: 38070481
Emerging evidence suggests that local tumor radiotherapy reshapes the repertoire of circulating myeloid-derived suppressor cells (MDSCs) and leads to their infiltration into the tumor microenvironment, which poses a major obstacle...
9.
Katipally R, Martinez C, Pugh S, Bridgewater J, Primrose J, Domingo E, et al.
JAMA Oncol
. 2023 Jul;
9(9):1245-1254.
PMID: 37471075
Importance: Personalized treatment approaches for patients with oligometastatic colorectal liver metastases are critically needed. We previously defined 3 biologically distinct molecular subtypes of colorectal liver metastases: (1) canonical, (2) immune,...
10.
Katipally R, Pitroda S, Weichselbaum R, Hellman S
Clin Cancer Res
. 2023 Apr;
29(15):2761-2766.
PMID: 37115507
The "oligometastasis" hypothesis proposes that metastases exist as a spectrum and are not always disseminated. According to this theory, a subset of patients with metastatic disease could benefit from aggressive...